ArticleScientific reports2018
D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- Comparative antioxidant efficacy of D-Cateslytin combined with modified triple antibiotic paste and calcium hydroxide: anFrontiers in dental medicine · 2026Article
- Shaping the Future of Antimicrobial Therapy: Harnessing the Power of Antimicrobial Peptides in Biomedical Applications.Journal of functional biomaterials · 2023Review
- In Vitro Antifungal Activity of Three Synthetic Peptides againstAntibiotics (Basel, Switzerland) · 2023Article
- Investigation of the antifungal effects of curcumin against nystatin-resistantDental research journal · 2023Article
- Antimicrobial Proteins: Structure, Molecular Action, and Therapeutic Potential.Pharmaceutics · 2022Review
- Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care.Pharmaceutics · 2022Review
- Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022Review
- The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.International journal of molecular sciences · 2022Article
- The antimicrobial peptides secreted by the chromaffin cells of the adrenal medulla link the neuroendocrine and immune systems: From basic to clinical studies.Frontiers in immunology · 2022Review
- Catestatin in innate immunity and Cateslytin-derived peptides against superbugs.Scientific reports · 2021Article
- Au@Ag Core@Shell Nanoparticles Synthesized with Rumex hymenosepalus as Antimicrobial Agent.Nanoscale research letters · 2021Article
- Self-defensive antimicrobial biomaterial surfaces.Colloids and surfaces. B, Biointerfaces · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The excessive use of antifungal agents, compounded by the shortage of new drugs being introduced into the market, is causing the accumulation of multi-resistance phenotypes in many fungal strains. Consequently, new alternative molecules to conventional antifungal agents are urgently needed to prevent the emergence of fungal resistance. In this context, Cateslytin (Ctl), a natural peptide derived from the processing of Chromogranin A, has already been described as an effective antimicrobial agent against several pathogens including Candida albicans. In the present study, we compared the antimicrobial activity of two conformations of Ctl, L-Ctl and D-Ctl against Candida albicans. Our results show that both D-Ctl and L-Ctl were potent and safe antifungal agents. However, in contrast to L-Ctl, D-Ctl was not degraded by proteases secreted by Candida albicans and was also stable in saliva. Using video microscopy, we also demonstrated that D-Ctl can rapidly enter C. albicans, but is unable to spread within a yeast colony unless from a mother cell to a daughter cell during cellular division. Besides, we revealed that the antifungal activity of D-Ctl could be synergized by voriconazole, an antifungal of reference in the treatment of Candida albicans related infections. In conclusion, D-Ctl can be considered as an effective, safe and stable antifungal and could be used alone or in a combination therapy with voriconazole to treat Candida albicans related diseases including oral candidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.